Ongoing investigations and new uses of radioimmunotherapy in the treatment of non-Hodgkin's lymphoma

International Journal of Radiation Oncology Biology Physics

Volumn 66, Issue SUPPL. 2, 2006, Pages

  Meredith, Ruby F ^a  

^a The University of Alabama at Birmingham   (United States)

Author keywords

Ibritumomab tiuxetan; non Hodgkin's lymphoma; Radionuclide therapy; Tositumomab

Indexed keywords

CELLS; MEDICAL APPLICATIONS; ONCOLOGY; PATIENT TREATMENT; RADIOISOTOPES; TUMORS;

IBRITUMOMAB TIUXETAN; NON-HODGKIN'S LYMPHOMA; RADIONUCLIDE THERAPY; TOSITUMOMAB;

RADIOTHERAPY;

CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IBRITUMOMAB TIUXETAN; INTERLEUKIN 11; MELPHALAN; PREDNISONE; RITUXIMAB; TOSITUMOMAB I 131; VINCRISTINE;

ANEMIA; ARTICLE; B CELL LYMPHOMA; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; CLINICAL TRIAL; DISEASE SEVERITY; DOSE RESPONSE; DOSIMETRY; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; EXTERNAL BEAM RADIOTHERAPY; FEBRILE NEUTROPENIA; FOLLICULAR LYMPHOMA; HUMAN; ISOTOPE LABELING; LARGE CELL LYMPHOMA; MANTLE CELL LYMPHOMA; NEUTROPENIA; NONHODGKIN LYMPHOMA; OUTCOME ASSESSMENT; PEDIATRICS; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; RADIOISOTOPE THERAPY; STEM CELL TRANSPLANTATION; SYSTEMIC TARGETED RADIONUCLIDE THERAPY; THERAPY EFFECT; THROMBOCYTOPENIA; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; CLINICAL TRIALS; HUMANS; LYMPHOMA, NON-HODGKIN; RADIOIMMUNOTHERAPY; YTTRIUM RADIOISOTOPES;

EID: 33748468145     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2006.05.068     Document Type: Article

References (47)

1. Kaminski M.S., Zelenetz A.D., Press O.W., et al. Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol 19 (2001) 3918-3928
2. Witzig T.E., Flinn I.W., Gordon L.I., et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol 20 (2002) 3262-3269
3. Macklis R., Molina A., Pohlman B., et al. Long-term responses in patients with relapsed or refractory follicular lymphoma treated with yttrium 90 ibritumomab tiuxetan (Zevalin). Int J Radiat Oncol Biol Phys 60 Suppl (2004) S542-S543
4. Knox S.J., Meredith R.F., Coleman M., et al. Tositumomab and iodine I 131 tositumomab (BEXXAR therapeutic regimen) produces long-term durable responses in heavily pretreated patients with relapsed, refractory, and transformed low-grade non-Hodgkin's lymphoma (NHL). Int J Radiat Oncol Biol Phys 60 Suppl (2004) S220
5. Witzig T.E., White C.A., Gordon L.I., et al. Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-Hodgkin's lymphoma. J Clin Oncol 21 (2003) 1263-1270
6. Gregory S.A., Leonard J.P., Knox S.J., et al. The iodine I-131 tositumomab therapeutic regimen: Summary of safety in 995 patients with relapsed/refractory low grade (LG) and transformed LG non-Hodgkin's lymphoma (NHL). [Abstract]. Proc Am Soc Clin Oncol 23 (2004) 613
7. Bodei L., Cremonesi M., Grana C., et al. Receptor radionuclide therapy with 90Y-[DOTA]0-Tyr3-octreotide (90Y-DOTATOC) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging 31 (2004) 1038-1046
8. National Cancer Institute. Comparative trial between Bexxar and Zevalin. National Cancer Institute Web site. Available online at: http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=361581&version=HealthProfessional&protocolsearchid=1535990; Protocol ID: CCBX001-053. Accessed April 24, 2006.
9. Mac Manus M.P., and Hoppe R.T. Is radiotherapy curative for stage I and II low-grade follicular lymphoma?. Results of a long-term follow-up study of patients treated at Stanford University. J Clin Oncol 14 (1996) 1282-1290
10. Gospodarowicz M.K., Bush R.S., Brown T.C., et al. Prognostic factors in nodular lymphomas: A multivariate analysis based on the Princess Margaret Hospital experience. Int J Radiat Oncol Biol Phys 10 (1984) 489-497
11. van Besien K., Sobocinski K.A., Rowlings P.A., et al. Allogeneic bone marrow transplantation for low-grade lymphoma. Blood 92 (1998) 1832-1836
12. Press O.W., Unger J.M., Braziel R.M., et al. A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group protocol S9911. Blood 102 (2003) 1606-1612
13. National Cancer Institute. Phase III randomized study of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) with either rituximab or iodine I 131 tositumomab (monoclonal antibody anti-B1) in patients with newly diagnosed follicular non-Hodgkin's lymphoma. National Cancer Institute Web site. Available online at: http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=68321&version=HealthProfessional&protocolsearchid=1528661; Protocol ID: SWOG-S0016. Accessed April 24, 2006.
14. Link B., Kaminski M.S., Coleman M., et al. Phase II study of CVP followed by tositumomab and iodine I 131 tositumomab (Bexxar therapeutic regimen) in patients with untreated follicular non-Hodgkin's lymphoma (NHL). [Abstract]. Proc Am Soc Clin Oncol 23 (2004) 560
15. Leonard J.P., Coleman M., Kostakoglu L., et al. Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine I 131 tositumomab for untreated follicular lymphoma. J Clin Oncol 23 (2005) 5696-5704
16. Shipley D.L., Greco F.A., Spigel D.R., et al. Rituximab with short duration chemotherapy followed by 90Y ibritumomab tiuxetan as first-line treatment for patients with follicular lymphoma: Update of a Minnie Pearl Cancer Research Network phase II trial. [Abstract]. J Clin Oncol 23 Suppl (2005) 579s
17. Radford J.A., Ketterer N., Sebban C., et al. Ibritumomab tiuxetan (Zevalin™) therapy is feasible and safe for the treatment of patients with advanced B-cell follicular NHL in first remission: Interim analysis for safety of a multicenter, phase III clinical trial. [Abstract]. Blood 102 (2003) 408-409a
18. Meredith R.F., and Knox S.J. Clinical development of radioimmunotherapy for B-cell non-Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys 66 Suppl. 1 (2006) S15-S22
19. Kaminski M.S., Tuck M., Estes J., et al. 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med 352 (2005) 441-449
20. 90Y) ibritumomab tiuxetan (Zevalin) therapy with rituximab maintenance in patients with untreated low-grade follicular lymphoma. [Abstract]. Blood 104 (2004) 720a
21. Forero-Torres A., Besh S., Knox S., et al. Higher doses of Rituxan alter pharmacokinetics and biodistribution of Zevalin but may increase responses: A preliminary report of a phase I study of Zevalin using a modified treatment regimen for relapsed or refractory CD20+ B-cell follicular/transformed non-Hodgkin's lymphoma. [Abstract]. Blood 102 (2003) 408a
22. Kaminski M.S., Radford J.A., Gregory S.A., et al. Re-treatment with I-131 tositumomab in patients with non-Hodgkin's lymphoma who had previously responded to I-131 tositumomab. J Clin Oncol 23 (2005) 7985-7993 Erratum in: J Clin Oncol 2006;24:212
23. Witzig T.E., Wiseman G.A., Geyer S.M., et al. A phase I trial of two sequential doses of Zevalin radioimmunotherapy for relapsed low-grade B-cell non-Hodgkin's lymphoma. [Abstract]. Blood 102 (2003) 406a
24. National Cancer Institute. Phase I study of yttrium Y 90 ibritumomab tiuxetan and rituximab with and without filgrastim (G-CSF) and interleukin-11 in patients with relapsed or refractory low-grade or follicular CD20+ non-Hodgkin's lymphoma. National Cancer Institute Web site. Available online at: http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=68503&version=HealthProfessional&protocolsearchid=1535990; Protocol ID: MAYO-MC998C. Accessed April 24, 2006.
25. Ansell S.M., Ristow K.M., Habermann T.M., et al. Subsequent chemotherapy regimens are well tolerated after radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for non-Hodgkin's lymphoma. J Clin Oncol 20 (2002) 3885-3890
26. Ansell S.M., Schilder R.J., Pieslor P.C., et al. Antilymphoma treatments given subsequent to yttrium 90 ibritumomab tiuxetan are feasible in patients with progressive non-Hodgkin's lymphoma: A review of the literature. Clin Lymphoma 5 (2004) 202-204
27. Vose J.M., Bierman P.J., Lynch J.C., et al. Phase I clinical trial of Zevalin (90Y-ibritumomab) in patients with B-cell non-Hodgkin's lymphoma (NHL) with relapsed disease following high-dose chemotherapy and autologous stem cell transplantation (ASCT). [Abstract]. Blood 102 (2003) 30a
28. 90Y ibritumomab tiuxetan therapy is safe in patients with prior myeloablative chemotherapy. Clin Cancer Res 11 (2005) 7146s-7150s
29. Liu S.Y., Eary J.F., Petersdorf S.H., et al. Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologous stem-cell rescue. J Clin Oncol 16 (1998) 3270-3278
30. Press O.W., Eary J.F., Gooley T., et al. A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. Blood 96 (2000) 2934-2942
31. 90Y) ibritumomab tiuxetan with high-dose chemotherapy, in elderly patients with non-Hodgkin's lymphoma (NHL). [Abstract]. J Clin Oncol 23 Suppl (2005) 576s
32. 90Y ibritumomab tiuxetan (Zevalin; 90YZ) doses higher than 4 mCi/kg may be safely combined with high-dose BEAM and autotransplant: The role for dosimetry. [Abstract]. Blood 104 (2004) 329a
33. Nademanee A., Forman S., Molina A., et al. A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma. Blood 106 (2005) 2896-2902
34. 90Y) ibritumomab tiuxetan with autologous stem cell transplantation (ASCT) in patients with relapsed or refractory non-Hodgkin's lymphoma (NHL). [Abstract]. Blood 11 (2004) 256a
35. 90Y-It) in children with recurrent/refractory CD20 positive lymphoma: A COG phase I consortium study. [Abstract]. Blood 106 (2005) 688a-689a
36. Gordon L.I., Molina A., Witzig T., et al. Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: Long-term follow-up of a phase 1/2 study. Blood 103 (2004) 4429-4431
37. Morschhauser F., Huglo D., Martinelli G., et al. Yttrium-90 ibritumomab tiuxetan (Zevalin) for patients with relapsed/refractory diffuse large B-cell lymphoma not appropriate for autologous stem cell transplantation: Results of an open-label phase II trial. [Abstract]. Blood 104 (2004) 41a
38. Hamlin P.A., Moskowitz C.H., Wegner B.C., et al. Early safety and efficacy analysis of a phase II study of sequential R-CHOP and yttrium-90 ibritumomab tiuxetan (Zevalin) for elderly high risk patients with untreated DLBCL. [Abstract]. Blood 106 (2005) 272a
39. National Cancer Institute. Phase II study of rituximab, prednisone, cyclophosphamide, doxorubicin, and vincristine followed by rituximab and yttrium Y 90 ibritumomab tiuxetan in patients with stage I or II CD20-positive diffuse large cell lymphoma. National Cancer Institute Web site. Available online at: http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=377493&version=HealthProfessional&protocolsearchid=1385617; Protocol ID: ECOG-E3402. Accessed April 24, 2006.
40. Witzig T.E., White C.A., Wiseman G.A., et al. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20+ B-cell non-Hodgkin's lymphoma. J Clin Oncol 17 (1999) 3793-3803
41. Zelenetz A.D., Donnelly G., Halaas J., et al. Initial treatment of mantle cell lymphoma with sequential radioimmunotherapy with tositumomab/iodine I131 I-tositumomab followed by CHOP chemotherapy results in a high complete remission rate. [Abstract]. Blood 102 (2003) 406a
42. 90Y) ibritumomab tiuxetan (Zevalin) in 22 patients with relapsed and refractory mantle cell lymphoma (MCL). [Abstract]. Blood 106 (2005) 689a-690a
43. National Cancer Institute. Phase II study of rituximab and CHOP chemotherapy comprising prednisone, cyclophosphamide, doxorubicin, and vincristine followed by yttrium Y 90 ibritumomab tiuxetan (yttrium Y 90 Zevalin®) in patients with previously untreated mantle cell lymphoma. National Cancer Institute Web site. Available online at: http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=334470&version=HealthProfessional&protocolsearchid=1535990; Protocol ID: ECOG-1499. Accessed April 24, 2006.
44. National Cancer Institute. Phase II study of cyclophosphamide, doxorubicin, vincristine, and prednisone and radiotherapy followed by rituximab and yttrium Y 90 ibritumomab tiuxetan in patients with aggressive stage I or IE or non-bulky stage II or IIE CD20-positive non-Hodgkin's lymphoma. National Cancer Institute Web site. Available online at: http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=329864&version=HealthProfessional&protocolsearchid=1535990; Protocol ID: SWOG-S0313. Accessed April 24, 2006.
45. 90Y-Zevalin) versus rituximab monotherapy in patients with relapsed follicular lymphoma. [Abstract]. Blood 106 (2005) 685a
46. Williams E.N., and Papatheofanis F.J. Zevalin for the treatment of refractory or relapsing, low-grade or follicular non-Hodgkin's lymphoma (NHL): A cost-utility study (2003) 29 25th Annual Meeting of the Society of Medical Decision Making; October 22; Chicago, IL
47. Sharkey R.M., Burton J., and Goldenberg D.M. Radioimmunotherapy for non-Hodgkin's lymphoma: A critical appraisal. Expert Rev Clin Immunol 1 (2005) 47-62